Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH) (IHH)

  • STATUS
    Recruiting
  • End date
    Oct 1, 2025
  • participants needed
    210
  • sponsor
    Tongji Hospital
Updated on 4 March 2022
gonadotropin
pituitary
testosterone
follicle stimulating hormone
testosterone level
hormone levels
menotropins
pituitary hormones
klinefelter syndrome
secondary hypogonadism
idiopathic hypogonadotropic hypogonadism
blood testosterone
serum fsh level

Summary

This study will evaluate the efficacy and safety of long term use of hCG alone or hCG plus hMG in the treatment of male patients with isolated hypogonadotropic hypogonadism (IHH). One third of the participants will receive hCG treatment alone and the other third of the participants will receive hCG treatment alone for six months, then the hMG will be added. And the last third of the participants will receive hCG and hMG treatment since the beginning of the treatment.

Description

The efficacy of hCG alone or hCG plus hMG in the treatment of male IHH patients was reported in some studies. However, these studies were mostly non-randomized controlled studies with small size of samples and short follow-up time. There was also no reported study which aimed to compare the efficacy and safety of long term use of hCG or hCG plus hMG in the treatment of male patients with IHH. So the difference in the efficacy and safety between long term use of hCG alone and hCG plus hMG in the treatment of IHH is unknown. In different reported studies, the hCG plus hMG treatment had two regimens: using hCG alone for six month, then hMG was added and using hCG plus hMG since the beginning of the treatment. The difference in the efficacy and safety between the above two regimes is also unknown.

Details
Condition Isolated Hypogonadotropic Hypogonadism, Kallmann Syndrome, Infertility
Treatment human menopausal gonadotropin, Human Chorionic Gonadotropin
Clinical Study IdentifierNCT03687606
SponsorTongji Hospital
Last Modified on4 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18, 45 years old
Adolescent dysplasia or loss of puberty: Genital Tanner score 5, pubic hair Tanner score 5
Serum FSH and LH levels are low or in normal low value, testosterone was lower than normal range (1.75ng / ml, the lower limit of the normal blood testosterone reference range of Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology)
With or without olfactory loss/reduction
Other pituitary hormone levels are normal
Head MRI examination is normal
Fertility is desired currently or will be desired in the future
Understand and sign the informed consent form

Exclusion Criteria

Primary hypogonadism
Acquired hypogonadotrophic hypogonadism
A history of treatment with pulsed GnRH, hCG and FSH related hormones
Receive testosterone replacement therapy for more than 6 months
History of cryptorchidism or cryptorchidism
The sperm density before treatment 110^6/ml
Moderate or severe liver and kidney dysfunction (ALT>120IU/L, AST>80IU/L, CR>115mol/L)
The karyotype is 45,X or 47,XXY and 48, XXXY and other abnormal karyotypes
True hermaphroditism and pseudohermaphroditism
Sex hormone abnormalities caused by adrenal lesions
Hypogonadism secondary to other systemic diseases
Abnormal secretion of hormones caused by brain lesions (such as pituitary tumors)
There are other hormone abnormalities in the pituitary
There are contraindications for the treatment with hCG or hMG
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note